Logo image of APM

APTORUM GROUP LTD-CLASS A (APM) Stock Fundamental Analysis

NASDAQ:APM - Nasdaq - KYG6096M1226 - Common Stock - Currency: USD

0.91  -0.03 (-3.19%)

Fundamental Rating

3

Taking everything into account, APM scores 3 out of 10 in our fundamental rating. APM was compared to 566 industry peers in the Biotechnology industry. APM has a bad profitability rating. Also its financial health evaluation is rather negative. APM has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year APM was profitable.
In the past year APM has reported a negative cash flow from operations.
APM had negative earnings in 4 of the past 5 years.
In the past 5 years APM always reported negative operating cash flow.
APM Yearly Net Income VS EBIT VS OCF VS FCFAPM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M

1.2 Ratios

APM's Return On Assets of 0.11% is amongst the best of the industry. APM outperforms 90.64% of its industry peers.
With an excellent Return On Equity value of 0.08%, APM belongs to the best of the industry, outperforming 91.52% of the companies in the same industry.
Industry RankSector Rank
ROA 0.11%
ROE 0.08%
ROIC N/A
ROA(3y)-58.32%
ROA(5y)-47.75%
ROE(3y)-59.95%
ROE(5y)-55.8%
ROIC(3y)N/A
ROIC(5y)N/A
APM Yearly ROA, ROE, ROICAPM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80 -100

1.3 Margins

APM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APM Yearly Profit, Operating, Gross MarginsAPM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

More info and screens

2

2. Health

2.1 Basic Checks

APM does not have a ROIC to compare to the WACC, probably because it is not profitable.
APM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for APM has been reduced compared to 5 years ago.
APM has a better debt/assets ratio than last year.
APM Yearly Shares OutstandingAPM Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
APM Yearly Total Debt VS Total AssetsAPM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -7.40, we must say that APM is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of APM (-7.40) is worse than 68.37% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that APM is not too dependend on debt financing.
APM has a worse Debt to Equity ratio (0.14) than 67.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -7.4
ROIC/WACCN/A
WACC7.31%
APM Yearly LT Debt VS Equity VS FCFAPM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M 40M

2.3 Liquidity

APM has a Current Ratio of 1.17. This is a normal value and indicates that APM is financially healthy and should not expect problems in meeting its short term obligations.
APM has a worse Current ratio (1.17) than 86.40% of its industry peers.
APM has a Quick Ratio of 1.17. This is a normal value and indicates that APM is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.17, APM is doing worse than 84.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 1.17
APM Yearly Current Assets VS Current LiabilitesAPM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 100.48% over the past year.
APM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
APM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.57% yearly.
EPS 1Y (TTM)100.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.27%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-22.03%
Revenue growth 5Y2.57%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 262.38% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 96.87% on average over the next years. This is a very strong growth
EPS Next Y86.79%
EPS Next 2Y262.38%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9197.28%
Revenue Next 2Y347.73%
Revenue Next 3Y145.13%
Revenue Next 5Y96.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
APM Yearly Revenue VS EstimatesAPM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
APM Yearly EPS VS EstimatesAPM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 45.50, the valuation of APM can be described as expensive.
93.64% of the companies in the same industry are more expensive than APM, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of APM to the average of the S&P500 Index (28.88), we can say APM is valued expensively.
With a Price/Forward Earnings ratio of 0.02, the valuation of APM can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of APM indicates a rather cheap valuation: APM is cheaper than 100.00% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of APM to the average of the S&P500 Index (21.20), we can say APM is valued rather cheaply.
Industry RankSector Rank
PE 45.5
Fwd PE 0.02
APM Price Earnings VS Forward Price EarningsAPM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APM Per share dataAPM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40 50

4.3 Compensation for Growth

APM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
APM's earnings are expected to grow with 262.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.52
PEG (5Y)N/A
EPS Next 2Y262.38%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

APM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APTORUM GROUP LTD-CLASS A

NASDAQ:APM (5/1/2025, 10:19:10 AM)

0.91

-0.03 (-3.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-28 2025-04-28/amc
Earnings (Next)N/A N/A
Inst Owners0.89%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap6.50M
Analysts80
Price TargetN/A
Short Float %1.29%
Short Ratio0.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 45.5
Fwd PE 0.02
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.29
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)0.02
EY2.2%
EPS(NY)59.59
Fwd EY6548.35%
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0
BVpS3.17
TBVpS3.17
PEG (NY)0.52
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.11%
ROE 0.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.32%
ROA(5y)-47.75%
ROE(3y)-59.95%
ROE(5y)-55.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 1.17
Altman-Z -7.4
F-Score3
WACC7.31%
ROIC/WACCN/A
Cap/Depr(3y)9.24%
Cap/Depr(5y)25.03%
Cap/Sales(3y)8.13%
Cap/Sales(5y)49.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.27%
EPS Next Y86.79%
EPS Next 2Y262.38%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-22.03%
Revenue growth 5Y2.57%
Sales Q2Q%-100%
Revenue Next Year9197.28%
Revenue Next 2Y347.73%
Revenue Next 3Y145.13%
Revenue Next 5Y96.87%
EBIT growth 1Y63.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year96.61%
EBIT Next 3Y58.29%
EBIT Next 5Y49.53%
FCF growth 1Y81.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y81.01%
OCF growth 3YN/A
OCF growth 5YN/A